Health-related quality of life in patients with newly diagnosed inflammatory bowel disease: an observational prospective cohort study (IBSEN III).

"Declarations Conflict of interestBCO, RO, CL, TBA, IJ, KH, M-BB, PR, TB, L-PJJ and GHH declare no conflicts of interest. VAK received speaker fees from Janssen-Cilag AS, consultant and scientific board fees from Takeda AS, and advisory board fees from Tillotts Pharma AG. MLH received speaker fees from Galapagos, Ferring, BMS, Janssen, AbbVie, Meda, Tillotts, and Takeda; is on the advisory boards of Takeda, Galapagos, BMS, and AbbVie; and initiated research grants from Takeda, Pfizer, Tillotts, and Ferring. VS received grants from Takeda AS. TED has served as a speaker, consultant, or advisory board member for AbbVie, Ferring, Pfizer, Pharmacosmos, Tillotts, and Vifor Pharma. He also received unrestricted research grants from AbbVie and Pharmacosmos. Ethics approvalThis study was approved by the Southeast Regional Committee for Medical Research Ethics (REC Southeast) (ref 2015/946-3) and the Norwegian Center for Research Data (NSD, 498873). Study inclusion did not imply any changes in patient treatment, and the study was conducted in accordance with the revised Declaration of Helsinki. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement was reviewed before submission to improve quality of the work [40]. Consent to participateWritten informed consent was obtained from all individual participants included in the study. Consent to publishThe authors affirm that human research participants provided informed consent for publication. Conflict of interest BCO, RO, CL, TBA, IJ, KH, M-BB, PR, TB, L-PJJ and GHH declare no conflicts of interest. VAK received speaker fees from Janssen-Cilag AS, consultant and scientific board fees from Takeda AS, and advisory board fees from Tillotts Pharma AG. MLH received speaker fees from Galapagos, Ferring, BMS, Janssen, AbbVie, Meda, Tillotts, and Takeda; is on the advisory boards of Takeda, Galapagos, BMS, and AbbVie; and initiated research grants from Takeda, Pfizer, Tillotts, and Ferring. VS received grants from Takeda AS. TED has served as a speaker, consultant, or advisory board member for AbbVie, Ferring, Pfizer, Pharmacosmos, Tillotts, and Vifor Pharma. He also received unrestricted research grants from AbbVie and Pharmacosmos."

"Funding Open access funding provided by Telemark Hospital Trust. The IBSEN III study was fully investigator-initiated and received funding from Takeda Pharmaceuticals, Pfizer, Ferring Pharmaceuticals, Tillotts Pharma, Dam Foundation, and South-Eastern Health Authorities."